ArticleAsian Pacific journal of cancer prevention : APJCP2025
Serum Biomarkers in Thyroid Malignancies: Evaluating Thyroid-Stimulating Hormone Receptor (TSHR) and Vascular Adhesion Protein-1 (VAP-1) as Potential Diagnostic Biomarker.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer is a prevalent endocrine malignancy, and identifying reliable molecular markers is crucial. This study evaluates the diagnostic potential of the thyroid-stimulating hormone receptor (TSHR) and vascular adhesion protein-1 (VAP-1). MATERIALS AND
methodsA total of 90 patients with thyroid disorders including malignant tumors, benign tumors, and hyperthyroidism were recruited from the Al-Amal National Hospital for Cancer Management in Baghdad (March-June 2022). Twenty-five age-matched healthy individuals served as controls. Serum levels of T3, T4, TSH, and thyroglobulin (Tg) were measured along with TSHR and VAP-1 using commercial sandwich ELISA kits.
resultsPatients with thyroid cancer exhibited significantly elevated levels of T3 and T4, as well as markedly increased Tg concentrations, compared to controls. In contrast, TSH levels were significantly reduced (P < 0.001). Notably, VAP-1 levels were significantly lower in thyroid cancer patients when compared with both healthy controls and patients with other thyroid disorders (P < 0.001), while TSHR levels did not differ significantly among the groups.
conclusionThe distinct hormonal profile observed characterized by increased T3, T4, and Tg, alongside a significant reduction in VAP-1 suggests that low serum VAP-1 may serve as a useful diagnostic marker for thyroid cancer. These findings underscore the complex interplay between thyroid function and tumor biology and warrant further investigation into the molecular mechanisms underlying these alterations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.